BioCentury
ARTICLE | Finance

Shanghai’s STAR rises as a destination for biotech IPOs

Shanghai’s STAR market could soon see a burst of biotech IPOs to rival the activity on HKEX

November 16, 2019 4:40 AM UTC
Updated on Nov 16, 2019 at 4:53 AM UTC

An analysis of recent and expected IPOs of Chinese biotechs suggests Shanghai’s STAR market could quickly catch up to, or even surpass, HKEX in the number of biotechs completing IPOs on the exchange.

Since Hong Kong Exchanges and Clearing Ltd. (HKEX) opened its prerevenue chapter in April 2018, 12 Chinese drug developers have opted to go public on the exchange, while only one Chinese therapeutics company had its IPO on NASDAQ during the period...